

1 **Recent advances in technologies for vitamin A**  
2 **protection in foods**

3

4 S. M. Loveday                      s.loveday@massey.ac.nz

5 H. Singh\*                              h.singh@massey.ac.nz

6

7 Riddet Institute

8 Massey University

9 Private Bag 11 222

10 Palmerston North

11 NEW ZEALAND

12

13 \* Corresponding author.

14 Tel.: +64 6 350 4401

15 Fax: +64 6 350 5655

## 16 **Abstract**

17 Vitamin A deficiency affects many children in the developing world,  
18 and is preventable via food or pharmaceutical supplementation. The  
19 main technical barrier to the fortification of food with vitamin A is its  
20 susceptibility to oxidation and isomerization, which result in loss of  
21 nutritional efficacy. This review discusses recent technological  
22 avenues for stabilizing vitamin A in foods.

## 23 **Key Words**

24 vitamin A, retinoids, encapsulation, nutrition, nutraceutical, food  
25 fortification, oxidation, isomerization, nanotechnology

## 26 **Introduction**

27 'Vitamin A' refers to a group of polyunsaturated hydrocarbons with  
28 important nutritional roles in humans. The main compounds in this  
29 group are the retinoids, which are chemical derivatives of retinol (Fig.  
30 1), and provitamin A carotenoids, which are partially converted to  
31 retinoids *in vivo*.

32 Adequate intake of vitamin A is vital to childhood development  
33 because of its role in vision and ocular health, immune system  
34 development, and neurological function. Vitamin A deficiency is a  
35 major cause of death and disease in the developing world, especially  
36 among mothers and infants.. Supplementation with large,  
37 pharmaceutically administered doses of vitamin A can substantially  
38 reduce the incidence and severity of some infectious diseases  
39 (Villamor & Fawzi, 2005).

40 Fortification of foods is another strategy for combating vitamin A  
41 deficiency, but fortification is not straightforward, for several reasons.  
42 Firstly, as vitamin A is accumulated in the adipose tissue and high  
43 levels are acutely toxic, the fortification of processed foods must be  
44 regulated to avoid excessive vitamin A intake (Dary & Mora, 2002).  
45 Secondly, vitamin A is poorly dispersible in aqueous systems such as  
46 beverages and high moisture foods. Finally, vitamin A is highly labile  
47 under ambient conditions, a problem that affects both food and  
48 pharmaceutical supplementation routes. Large losses of vitamin A  
49 activity can occur during processing, transportation and storage of  
50 fortified foods (Dary & Mora, 2002). Adding vitamin A above the  
51 intended fortification level to compensate for losses is undesirable  
52 because of the potential for overdosing.

53 Technologies that enhance the stability of vitamin A in foods are  
54 required for ensuring the safety and efficacy of the vitamin A  
55 fortification of foods. This paper briefly discusses the factors affecting  
56 vitamin A stability and then discusses the present state of the art in  
57 vitamin A delivery technologies.

## 58 **Chemical instability of vitamin A**

59 The conjugated double bond system of retinoids (Fig. 1) and  
60 carotenoids presents an electron-dense region that is attractive to  
61 electron-deficient species, especially radicals. Retinoid degradation  
62 displays characteristics that are typical of radical reactions – catalysis  
63 by light, transition metals and free-radical-producing substances, and  
64 inhibition by free-radical-quenching chemicals. Principles developed

65 in the study of polyunsaturated lipid reactions are relevant to retinoid  
66 chemistry because of the common polyene chain (see Frankel,  
67 (2005). The oxidation pathways for retinoids have been discussed in  
68 a number of reviews, e.g. El-Agamey *et al.* (2004).

69 The double bonds in the polyene chain of retinoids can undergo  
70 *cis-trans* isomerization, especially at positions 9, 11 and 13. *All-trans*  
71 retinoids are predominant in food but minor amounts of other isomers  
72 may also be present (Brinkmann, Dehne, Oei, Tiebach, & Baltes,  
73 1995). *All-trans* retinol has maximal vitamin A activity, but  
74 isomerization during the processing and storage of food (Ball, 1998)  
75 results in partial loss of activity (Table 1). Several reaction schemes  
76 for geometric isomerization have been proposed, e.g. Rozanowska  
77 *et al.* (2005), but mechanistic understanding of isomerization  
78 reactions is limited. Heat-induced isomerization of retinoids produces  
79 mainly 13-*cis* isomers in milk (Panfili, Manzi, & Pizzoferrato, 1998).

80 Oxygen accelerates photo-catalysed degradation of retinoids under  
81 some circumstances, but degradation in the presence of oxygen is  
82 relatively slow without a catalyst such as light or chemically  
83 generated free radicals (Failloux, Bonnet, Perrier, & Baron, 2004).

84 Degradation of vitamin A in foods is accelerated by exposure to light,  
85 especially ultraviolet light at wavelengths below 415 nm (Garcia-  
86 Fuentes, Torres, & Alonso, 2003). Retinoids are degraded faster  
87 under ultraviolet-A light (UV-A, 315–400 nm) than under ultraviolet-B  
88 light (UV-B, 280–315 nm) (Failloux *et al.*, 2004).

## 89 **Technologies for stabilizing retinoids**

90 The degradation of retinoids in aqueous solution is rapid (Semenova,  
91 Cooper, Wilson, & Converse, 2002), and the solubility of retinoids in  
92 aqueous solvents is poor because of their low polarity. Dispersibility  
93 and stability can be improved by incorporating retinoids into colloidal  
94 carrier particles. Carriers include single and double emulsions,  
95 liposomes, solid lipid nanoparticles and polymeric micro- or  
96 nanoparticles. Complexing retinoids with molecular carriers, such as  
97 cyclodextrins and proteins, can also improve their stability.

98 Many of these technologies have been developed for cosmetic or  
99 pharmaceutical applications and their performance in food systems is  
100 poorly characterized. For example, the degradation of stabilized  
101 retinoids is often evaluated in model cosmetic emulsions or gels.

102 The efficiency with which an active agent (AA) is incorporated into a  
103 carrier matrix is expressed as a percentage, referred to as the  
104 entrapment efficiency:

$$105 \quad \text{entrapment efficiency} = \frac{\text{total AA} - \text{unentrapped AA}}{\text{total AA}} \times 100$$

106 The capacity of an encapsulation system to carry an AA, or 'loading  
107 capacity', is expressed as the percentage by weight of the 'capsule'  
108 phase (entrapped AA + matrix) that comprises AA:

$$109 \quad \text{loading capacity} = \frac{\text{entrapped AA}}{\text{entrapped AA} + \text{matrix}} \times 100$$

## 110           **1. Emulsion systems**

111 Retinoids can be incorporated into foods as emulsions using an oil-  
112 based carrier. The choice of carrier material is important because the  
113 oxidative stability of the incorporated retinoid is influenced by droplet  
114 physical characteristics (e.g. solid/liquid state, interfacial layer  
115 thickness) and chemical characteristics (e.g. degree of unsaturation,  
116 fatty acid chain length, presence of natural antioxidants). The basic  
117 principles of emulsion preparation and stabilization have recently  
118 been reviewed (McClements, Decker, & Weiss, 2007) and are not  
119 discussed here.

120 Surprisingly few applications of oil-in-water (O/W) emulsions to  
121 encapsulate retinoids are detailed in the scientific literature. A model  
122 cosmetic vehicle was developed in the work of Carlotti, Rossatto, and  
123 Gallarate (2002), in which vitamin A palmitate was dissolved in octyl  
124 octanoate and emulsified in water with Montanov 68 EC® (cetearyl  
125 alcohol and cetearyl glucoside). Vitamin A palmitate degraded  
126 slightly faster in an O/W emulsion than in bulk octyl octanoate, which  
127 was attributed to localization of vitamin A palmitate at the oil–water  
128 interface (Carlotti et al., 2002).

129 Several patents for the use of O/W emulsions to deliver fat-soluble  
130 vitamins into foods or pharmaceuticals have been filed (Hähnlein,  
131 Hanse, & Olesen, 1998; Yaghmur *et al.*, 2007).

132 Microemulsions are thermodynamically stable mixtures of water, oil  
133 and one or more amphiphiles, which assemble spontaneously into

134 nanometre-scale droplets (Flanagan & Singh, 2006). Suitable food-  
135 grade surfactants include ethoxylated mono- and diacylglycerides  
136 and phospholipids. Ethanol may be required as a co-surfactant to  
137 solubilize long chain triglycerides (Flanagan, Kortegaard, Pinder,  
138 Rades, & Singh, 2006).

139 O/W microemulsions are an efficient vehicle for incorporating  
140 hydrophobic nutrients into aqueous systems, e.g. lycopene (Garti,  
141 Yaghmur, Aserin, Spornath, Elfakess, & Ezrahi, 2004) and  $\beta$ -  
142 carotene (Szymula, 2004). On exposure to sunlight, lycopene  
143 degrades more slowly in O/W microemulsions than in an organic  
144 solvent (Garti et al., 2004). However, Szymula (2004) reported that  $\beta$ -  
145 carotene degradation in sunlight was fastest in O/W microemulsions,  
146 followed by water-in-oil (W/O) microemulsions and pure pentanol.  
147 Szymula (2004) suggested that the high concentration of  $\beta$ -carotene  
148 in oil droplets of the O/W microemulsion promoted degradation.  
149 Similar results have been reported with retinol in liposomes  
150 (Tesoriere, Darpa, Re, & Livrea, 1997).

151 A patent for the use of O/W or W/O microemulsions to deliver  
152 nutraceutical ingredients in foods has been granted (Garti, Abraham,  
153 Spornath, & Idit, 2007), and the technology is marketed by  
154 NutraLease Ltd (<http://www.nutralease.com>).

155 A double emulsion comprises either oil droplets inside water droplets,  
156 suspended in an oil-based continuous phase (oil-in-water-in-oil,  
157 O/W/O), or water droplets inside oil droplets in an aqueous  
158 continuous phase (water-in-oil-in-water, W/O/W).

159 Yoshida, Sekine, Matsuzaki, Yanaki, and Yamaguchi (1999) made  
160 O/W/O emulsions in which the outer oil phase contained an  
161 organophilic clay and a non-ionic surfactant. Retinol was  
162 incorporated into different types of emulsions, and stability decreased  
163 in the order O/W/O > W/O > O/W. Yoshida *et al.* (1999) attributed  
164 the stabilizing effect of the O/W/O emulsion to the exclusion of  
165 oxygen from the inner oil phase by a surrounding water layer. Retinol  
166 in the outer continuous phase of the W/O emulsion was more stable  
167 than retinol in the disperse phase of the O/W emulsion, which does  
168 not seem to be consistent with this theory. Retinol stability was  
169 thought to be inadvertently compromised by lipid peroxide impurities  
170 in the surfactant and metallic impurities in the clay, and stability was  
171 improved by both water-soluble and oil-soluble antioxidants (Yoshida  
172 *et al.*, 1999).

## 173           **2. Solid lipid nanoparticles**

174 Solid lipid nanoparticles (SLNs) with diameter 50–1000 nm have  
175 been used for the delivery of lipophilic drugs and cosmetics because  
176 they are well tolerated by the body (Müller, Mäder, & Gohla, 2000).  
177 The carrier particles are made from lipids that solidify at room  
178 temperature to form a crystalline or amorphous undercooled matrix in  
179 which the AA is incorporated. To prepare SLNs, the AA (in this case  
180 retinol, retinoic acid or a retinol ester such as retinyl palmitate) is first  
181 solubilized in melted lipid, forming a 'melt', and nanoparticles are  
182 prepared from the melt in one of three ways (Müller *et al.*, 2000).



- 183 • Hot homogenization: the melt is dispersed in a hot aqueous  
184 solution of surfactant, homogenized at high pressure and then  
185 cooled to room temperature.
- 186 • Cold homogenization: the melt is cooled to room temperature and  
187 ground to microparticles. These are dispersed in cold surfactant  
188 solution and homogenized, which produces cavitation forces that  
189 are sufficient to break microparticles into nanoparticles.
- 190 • Microemulsion technique: the melt is dispersed in hot surfactant  
191 solution to generate a microemulsion, which is then added to a  
192 cold aqueous medium, causing solid lipid particles to precipitate.

193 Patents have been granted for the manufacture of SLNs by hot or  
194 cold homogenization (Lucks & Müller, 1996) and by the  
195 microemulsion technique (Gasco, 2002). Retinoid-loaded SLNs have  
196 been produced by hot homogenization (Carlotti, Sapino, Trotta,  
197 Battaglia, Vione, & Pelizzetti, 2005; Jennings & Gohla, 2000; Lim, Lee,  
198 & Kim, 2004) and the microemulsion technique (Carlotti *et al.*, 2005).

199 Three models of drug incorporation into the SLN matrix have been  
200 proposed: a homogeneous matrix, the outer shell enriched with AA  
201 and the inner core enriched with AA (Müller *et al.*, 2000). The three  
202 models are illustrated and discussed in more detail by McClements  
203 *et al.* (2007).

204 A number of parameters affect the internal and membrane structure  
205 of SLNs, their stability against aggregation and the protection  
206 imparted to an entrapped AA. Cortesi, Esposito, Luca, and Nastruzzi

207 (2002) investigated the effect of numerous processing parameters on  
208 SLN size, recovery and morphology.

### 209 **Manufacture method**

210 Cold homogenization favours a homogeneous matrix. In hot  
211 homogenization methods, a shell rich in AA is formed if the lipid  
212 crystallizes before the AA. If the AA crystallizes at a lower  
213 temperature than the matrix, an enriched core forms. *All-trans* retinol  
214 melts at 62–64°C (Schwieter & Isler, 1971).

### 215 **Surfactant system**

216 Lim and Kim (2002) reported that the incorporation of *all-trans*  
217 retinoic acid into tricaprln SLNs was improved at higher surfactant  
218 levels (which also produced smaller particles). They took this to  
219 indicate that retinoic acid was incorporated into the surfactant layer  
220 rather than into the lipid matrix. At constant surfactant level and  
221 composition, retinol stability improved with decreasing particle size  
222 and increasing total surface area (Müller, Radtke, & Wissing, 2002),  
223 in agreement with the findings of Lim and Kim (2002).

224 The stability of SLNs against aggregation is affected by the ionic  
225 strength of the continuous phase and the charge density at the  
226 lipid–water interface (Garcia-Fuentes et al., 2003; Lim & Kim, 2002).  
227 A large zeta potential (positive or negative) helps to stabilize SLNs  
228 against aggregation, but non-electrostatic effects such as steric  
229 stabilization may also be important (Garcia-Fuentes et al., 2003).

230 Lim and Kim (2002) reported that the aggregation stability of SLNs  
231 loaded with all-*trans* retinoic acid could be optimized by altering the  
232 balance of surfactants. Stability was further improved by the inclusion  
233 of distearoylphosphatidyl ethanolamine–N-poly(ethylene glycol)  
234 (DSPE–PEG), a polymer with both steric- and electrostatic-stabilizing  
235 effects. In freeze-dried SLNs, retention of all-*trans* retinoic acid was >  
236 90% after 3 months of storage at 4°C (Lim et al., 2004).

### 237 **Lipid type**

238 The loading capacities of SLNs are limited by expulsion of the AA  
239 from lipid matrices as they crystallize (Müller *et al.*, 2000). Jennings  
240 and Gohla (2000) entrapped retinoids in a range of glycerides and  
241 waxes. Retention of the AA within the lipid matrix was poor with the  
242 waxes and tripalmitate, the lipids forming relatively pure crystals.

243 Mixed lipids form less perfect crystals, and the AA can be retained in  
244 the space created by crystal imperfections (Müller *et al.*, 2000). This  
245 type of SLN is sometimes termed a ‘nanostructured lipid carrier’  
246 (NLC) or ‘oil-loaded SLN’. Three types of structures are formed on  
247 cooling the lipid mixtures: imperfect crystals containing many  
248 imperfections, amorphous undercooled lipid and liquid lipid droplets  
249 in a solid lipid matrix (McClements et al., 2007).

250 Jores, Haberland, Wartewig, Mäder, and Mehnert (2005) found  
251 evidence that solid lipids in mixed-lipid SLNs crystallized in a platelet  
252 shape, expelling liquid lipid droplets to the surface. Liquid droplets  
253 containing a lipophilic marker were poorly protected from the external  
254 aqueous environment (Jores *et al.*, 2005). However, Garcia-Fuentes,

255 Alonso, and Torres (2005) produced tripalmitin SLNs with a short  
256 chain triacylglycerol that appeared to form oily domains within SLNs.

257 In the work of Jennings and Gohla (2001), the stability of retinol in  
258 glyceryl behenate SLNs was improved by adding a low melting  
259 medium chain triglyceride. Jennings and Gohla (2001) also reported  
260 that the stability of different retinoids in mixed-lipid SLNs followed the  
261 order of polarity: retinyl palmitate > retinol > retinoic acid.

262 Hu, Jiang, Du, Yuan, Ye, and Zeng (2005) produced nanoparticles  
263 from a mixture of stearic and oleic acids, and reported that increasing  
264 oleic acid content produced smoother particles with decreased  
265 crystallinity and increased drug loading capacity. Jennings and Gohla  
266 (2001) reported that adding 5–10% liquid lipid to SLNs improved the  
267 retinol loading capacity and stability, and postulated the existence of  
268 liquid and solid lipid domains within particles.

269 Carlotti *et al.* (2005) and Sapino, Carlotti, Pelizzetti, Vione, Trotta,  
270 and Battaglia (2005) tested the stability of retinyl palmitate in cetyl  
271 palmitate, glyceryl behenate and palmitic acid SLNs during exposure  
272 to UV light or prolonged storage. Stability was evaluated in model  
273 cosmetic systems – an O/W emulsion (Carlotti *et al.*, 2005) and a  
274 hydroxyethylcellulose gel (Sapino *et al.*, 2005). Retinyl palmitate in  
275 SLNs degraded more slowly than free retinyl palmitate. SLNs made  
276 with different lipids had similar light-scattering properties but the least  
277 polar lipid, cetyl palmitate, best protected retinyl palmitate against UV  
278 irradiation. This may have been due to improved retention of retinyl  
279 palmitate in the lipid matrix.

280 Mixed-lipid nanoparticle carriers have apparently not been patented.

### 281 **3. Liposomes**

282 Liposomes can be made by adding buffer to powdered phospholipid  
283 or a dried phospholipid film formed by rotary evaporation of an  
284 organic solvent. The organic solvents used in film formation are not  
285 acceptable in food.

286 Entrapment of retinoids in the lipid bilayers of multilamellar liposomes  
287 has been shown to improve their stability in the presence of oxygen  
288 (Lee, Yuk, Lee, Lee, Hwang, & Ludescher, 2002). Incorporation of  
289 retinol into liposomes at a retinol:phospholipid ratio of 1:100 is up to  
290 99% efficient, but liposomes offer little protection in acidic conditions  
291 or at temperatures at or above ambient (Lee et al., 2002). The  
292 process used to manufacture liposomes in this case used chloroform  
293 and methanol (Lee *et al.*, 2002). Retinol shows greater affinity than  
294 retinyl palmitate for entrapment into liposomes (Singh & Das, 1998).

295 Young and Gregoriadis (1996) reported that incorporating retinol into  
296 liposomes accelerated photodegradation relative to free retinol in  
297 methanol. Similarly, Tesoriere *et al.* (1997) found an increase in the  
298 retinol degradation rate with increasing concentration of liposome-  
299 encapsulated retinol. It was suggested that degradation reactions  
300 involving two retinol molecules were accelerated by concentrating  
301 retinol in liposomes (Young & Gregoriadis, 1996).

302 Liposome encapsulation can be combined with other mechanisms to  
303 enhance stability. Loukas, Jayasekera, and Gregoriadis (1995)

304 reported that the rate of riboflavin degradation under UV light was  
305 reduced up to 75% by incorporation into liposomes. Complexing  
306 riboflavin with  $\gamma$ -cyclodextrin slowed degradation by a further 80% at  
307 the expense of an approximately 50% reduction in entrapment  
308 efficiency (Loukas, Jayasekera, & Gregoriadis, 1995). McCormack  
309 and Gregoriadis (1998) reported 19% efficient entrapment of a  
310 retinol–hydroxypropyl  $\beta$ -cyclodextrin complex in liposomes but did  
311 not examine the effect on retinol oxidation or isomerization.

312 Liposomes can be stabilized against aggregation by coating with  
313 chitosan and incorporating them into microparticles (Ruan, Ng, &  
314 Feng, 2004). They can also encapsulate other particles, e.g.  
315 polymeric vesicles of palmitoyl glycol chitosan (McPhail, Tetley,  
316 Dufes, & Uchegbu, 2000).

317 In a related technology, lipid-soluble compounds can be incorporated  
318 into vesicles of a non-ionic surfactant (niosomes). Encapsulation of  
319  $\beta$ -carotene in niosomes comprising cholesterol and Tween or Span  
320 surfactants slows its degradation in sunlight and hydrogen peroxide  
321 solution, relative to free  $\beta$ -carotene (Palozza, Muzzalupo, Trombino,  
322 Valdannini, & Picci, 2006). Manconi, Valenti, Sinico, Lai, Loy, and  
323 Fadda (2003) tested a range of non-ionic surfactants for their ability  
324 to stabilize all-*trans* retinoic acid in niosomes irradiated with UV light,  
325 and found that two of the formulations improved stability relative to  
326 retinoic acid in methanol. However these authors used chloroform to  
327 manufacture niosomes, and for that reason the process is not  
328 suitable for food applications.

#### 329           **4. Cochleates**

330 Cochleates are micro- or nanoparticles consisting of phospholipid  
331 bilayers stacked as sheets and rolled into a spiral configuration with  
332 aqueous solutions of multivalent cations between each sheet  
333 (BioDelivery Sciences International, 2008). This is illustrated  
334 schematically in Fig. 2. Cochleates are prepared by slowly  
335 introducing polyvalent cations into anionic liposome suspensions,  
336 causing the liposomes to fuse.

337 In the ‘trapping’ method, calcium chloride is added dropwise to a  
338 liposome suspension, and cochleate formation is indicated by an  
339 immediate increase in turbidity (Evans & Zasadzinski, 2003). Small  
340 unilamellar liposomes prepared by film hydration give more uniform  
341 cigar-shaped cochleates than multilamellar liposomes from powdered  
342 phospholipids (Zarif, 2005).

343 For the ‘hydrogel process’, liposomes are mixed with a polymer such  
344 as dextran and injected into a solution of a second, non-miscible  
345 polymer, e.g. PEG. Calcium is added to the water-in-water emulsion  
346 and diffuses slowly from the PEG continuous phase into the  
347 dispersed dextran–liposome phase, producing nanocochleates  
348 (Santangelo *et al.*, 2000). Sub-micrometre cochleates can be  
349 produced with this method whereas the trapping method gives larger  
350 cochleates.

351 Cochleates are most frequently made with dioleoyl phosphatidyl  
352 serine and calcium chloride – natural ingredients that are acceptable  
353 in food systems (Evans & Zasadzinski, 2003; Walker, Kennedy, &

354 Zasadzinski, 1997). Calcium can be replaced with zinc ions (Zarif,  
355 Jin, Segarra, & Mannino, 2005) or organic cations (Jin, 2004).

356 Substances in the interior of liposomes are encapsulated in the  
357 cochleate when the cation is added. Santangelo *et al.* (2000)  
358 prepared cochleates from liposomes containing amphotericin B, a  
359 hydrophobic antimycotic drug. They used the hydrogel method,  
360 which gave cochleates with mean diameter 407 nm. The cochleate-  
361 encapsulated drug was highly effective against fungal infections in  
362 mice (Santangelo *et al.*, 2000). It appears that encapsulating  
363 retinoids in cochleates had not been attempted at the time of writing.

364 Cochleates can be used as intermediates for encapsulating small  
365 liposomes or colloidal particles, thus double-encapsulating labile  
366 substances (Evans & Zasadzinski, 2003; Walker *et al.*, 1997).  
367 Cations are chelated when EDTA is added to a suspension of  
368 colloidal particles and cochleates, causing the cochleates to unroll  
369 and close into vesicles around the particles. Walker *et al.* (1997)  
370 attached colloidal particles to cochleate phospholipids with specific  
371 ligand-receptor molecules, but the encapsulation efficiency was poor.

372 The company BioDelivery Sciences International Inc. has filed  
373 several US and international patents related to the incorporation of  
374 vitamin A in nanocochleates to enhance stability. Cochleate  
375 manufacture with the hydrogel method is claimed (Mannino &  
376 Krause-Elsmore, 2004), as is incorporation of liposomes into  
377 cochleates (Krause-Elsmore & Mannino, 2005) and several other  
378 applications (Zarif *et al.*, 2005).



## 379           **5. Cyclodextrin inclusion complexes**

380 Cyclodextrins (CDs) are rings of  $\alpha$ -1,4 bonded glucose molecules  
381 with a slightly hydrophobic interior that can entrap molecules less  
382 polar than water (Szejtli, 1998). Natural, underivatized CDs contain  
383 six, seven or eight glucose molecules and are referred to as  $\alpha$ -,  $\beta$ -  
384 and  $\gamma$ -CDs respectively. Methods for forming complexes between  
385 CDs and nutritional or pharmaceutical AAs have been reviewed by  
386 Szente (1996).

387 Retinoid-CD complexes have been prepared by mixing solutions at  
388 room temperature in aqueous ethanol (Semenova *et al.*, 2002) or  
389 methanol (Guo, Ren, Fang, & Liu, 1995). Another method is to form a  
390 film of retinoid on the surface of a flask, add aqueous CD solution to  
391 the flask and stir for several days (McCormack & Gregoriadis, 1998;  
392 Munoz-Botella, Martin, Del Castillo, Lerner, & Menendez, 2002).

393 Inclusion of unstable or poorly water-soluble molecules in CDs can  
394 improve their solubility in aqueous systems. For example, the  
395 aqueous solubility of all-*trans* retinoic acid increases by more than  
396 100 times after complexation with  $\beta$ -CD (Qi & Shieh, 2002) and more  
397 than 10 000 times after complexation with hydroxypropyl  $\beta$ -CD (Lin,  
398 Chean, Ng, Chan, & Ho, 2000). The solubility of the  $\beta$ -CD-retinoic  
399 acid complex is better at neutral pH than acidic pH (Lin *et al.*, 2000;  
400 Yap, Liu, Thenmozhiyal, & Ho, 2005). This may be because  $\text{COO}^-$   
401 groups of retinoic acid molecules, which are more ionized at neutral  
402 pH, can interact with the hydroxyl groups of CDs (Lin *et al.*, 2000).

403 The solubility of  $\beta$ -CD complexes can be improved by organic salts.  
404 Qi and Shieh (2002) reported a 26-fold increase in  $\beta$ -CD–retinoic  
405 acid complex with the addition of 1.5% sodium acetate. Sodium  
406 acetate also improves the solubility of hydrocortisone in  $\beta$ -CD, with  
407 an optimum concentration of 2% (Loftsson, Matthiasson, & Masson,  
408 2003). Some organic polymers enhance the solubilizing effect of  
409 CDs, e.g. carboxymethylcellulose (Qi & Shieh, 2002) and poly(vinyl  
410 pyrrolidone) (Loftsson & Brewster, 1996).

411 CDs have found widespread application in chromatographic methods  
412 and as drug carriers (Szejtli, 1998). Complexation of retinoids with  
413 CDs has been demonstrated by several groups (McCormack &  
414 Gregoriadis, 1998; Munoz-Botella et al., 2002; Yap et al., 2005).  
415 Semenova *et al.* (2002) reported good encapsulation and protection  
416 of all-*trans* retinol with two cyclodextrin formulations, but did not show  
417 sufficient data to verify this.

418 Association constants for several retinoid-cyclodextrin complexes are  
419 shown in Table 2. Binding is most favourable at neutral pH (Lin *et al.*,  
420 2000). Cyclodextrin binding studies have also been carried out on  
421 several cis-retinoids (Munoz-Botella et al., 2002; Yap et al., 2005)  
422 and carotenoids (Polyakov, Leshina, Konovalova, Hand, & Kispert,  
423 2004)

424 Complexing retinoids with CDs inhibits photoisomerization (Munoz-  
425 Botella *et al.*, 2002) and photodegradation (Yap *et al.*, 2005). The  
426 retinoid polyene chain is held in the CD cavity (Yap *et al.*, 2005),  
427 which dampens the torsion and rotation required for isomerization

428 (Munoz-Botella *et al.*, 2002). CD complexes of all-*trans* retinaldehyde  
429 photoisomerize preferentially to the 13-*cis* form but retinoic acid-CD  
430 complexes isomerize to a mixture of 9-, 11- and 13-*cis* isomers  
431 (Munoz-Botella *et al.*, 2002).

432 The molar ratio of CD to retinoid molecule in the inclusion complex is  
433 usually 1:1 or 2:1 (Guo *et al.*, 1995; Munoz-Botella *et al.*, 2002), but  
434 ratios as high as 4.5:1 have been reported (McCormack &  
435 Gregoriadis, 1998). The stoichiometry of the inclusion complex can  
436 change as a function of CD concentration, e.g. hydroxypropyl  $\beta$ -CD  
437 forms complexes with all-*trans* retinoic acid in a molar ratio of 1:1 at  
438 low CD concentration and in a molar ratio of 2:1 at higher CD  
439 concentration (Lin *et al.*, 2000).

440 CDs are already used in foods to encapsulate colours, flavours and  
441 polyunsaturated fatty acids, and to prevent turbidity in drinks.

442 The stabilizing effect of CDs on vitamin A has been known for some  
443 time, and was claimed in a 1955 US patent (Schlenk, Sand, &  
444 Tillotson, 1955). A number of Japanese patents have claimed  
445 methods for stabilizing vitamins with CD complexes, e.g. Takeshi and  
446 Okihiko (1994). In 1994, a US patent for a method of enhancing  
447 complexation between lipophilic food additives (including vitamin A)  
448 and CDs using natural or synthetic hydrophilic polymers was granted  
449 (Loftsson, 1994). Complexes of retinol or retinyl esters with  $\gamma$ -CDs  
450 are described in a 1999 US patent (Moldenhauer, Regiert, &  
451 Wimmer, 1999).

## 452           **6. Polymer encapsulation**

453 Polymers used for encapsulating retinoids in solid particles include  
454 proteins, polysaccharides and synthetic polymers. The choice of  
455 polymer in food systems is restricted by food regulations, and only  
456 food-safe solvents may be used in particle manufacture.  
457 Encapsulation of lipophilic drugs in polymer particles can be  
458 improved by complexation with CDs (Duchene, Ponchel, &  
459 Wouessidjewe, 1999).

460 Hwang, Oh, and Oh (2005) and Lee, Oh, Moon, and Bae (2001)  
461 successfully entrapped retinol in 0.5–10  $\mu\text{m}$  silica particles made  
462 using a multiple emulsion technique. Encapsulation efficiencies of  
463 7.4–30.9% (Hwang *et al.*, 2005) and 35.9–44.0% (Lee *et al.*, 2001)  
464 were achieved. In a similar procedure, Ribeiro, Neufeld, Arnaud, and  
465 Chaumeil (1999) produced chitosan-coated alginate microspheres,  
466 with mean diameter 500–800  $\mu\text{m}$ , containing soybean oil droplets  
467 and an oil-soluble marker dye. The marker dye was released slowly  
468 at pH 1.2 and faster at pH 7.5, and the speed of release depended  
469 on the thickness of the coating (Ribeiro *et al.*, 1999).

470 Polymer particles can be prepared by coacervation, which is also  
471 referred to as nanoprecipitation, drowning out or solvent  
472 displacement. In this technique, the polymer and the AA are  
473 dissolved in an organic solvent, which is emulsified in an aqueous  
474 surfactant solution. The solvent is evaporated from the O/W emulsion  
475 and the polymer precipitates, forming solid particles.

476 Biodegradable copolymers of lactic acid and glycolic acid (PLGA)  
477 have been widely used in drug delivery applications, and at least two  
478 research groups have encapsulated retinoids in copolymer  
479 microparticles (Cirpanli, Unlu, Calis, & Hincal, 2005; Jeong et al.,  
480 2003). Particles of 1–100  $\mu\text{m}$  were prepared with the coacervation  
481 technique, and an encapsulation efficiency of up to 74% was  
482 reported (Cirpanli et al., 2005; Jeong et al., 2003). However, the  
483 solvents commonly used to dissolve PLGA polymers are not  
484 permitted in food systems.

485 Since the 1950s, vitamin A has been encapsulated in solid gelatin  
486 beadlets for incorporation into animal feeds. In this process, an  
487 emulsion containing antioxidants, starch, gelatin and sugars, is spray  
488 congealed and the beadlet is cross linked by thermal or chemical  
489 means. Other protein encapsulants include collagen and gliadin.

490 Gliadin is a hydrophobic wheat protein that is insoluble in water but  
491 soluble in 70% ethanol. Hydrophobic AAs can be entrapped in gliadin  
492 nanoparticles by coacervation. Gliadin particles of about 500 nm with  
493 a payload of 76.4  $\mu\text{g}$  of retinoic acid per milligram of protein were  
494 prepared by Duclairoir, Irache, Nakache, Orecchioni, Chabenat, and  
495 Popineau (1999). These workers demonstrated controlled release of  
496 retinoic acid over 3 h, but did not examine degradation of the  
497 entrapped retinoic acid. Preparation of gliadin-coated lipid particles  
498 using a salting-out method has also been reported (Mauguet,  
499 Legrand, Brujes, Carnelle, Larre, & Popineau, 2002).

500 Swatschek, Schatton, Müller, and Kreuter (2002) used microparticles  
501 of marine sponge collagen (120–300 nm) as carriers for retinol  
502 adsorbed on the surface. In a model cosmetic cream containing  
503 retinol-loaded collagen particles, retention was over 50% after 8  
504 weeks at 21°C.

505 It was recently reported that nanoparticle complexes can be formed  
506 in mixtures of gum arabic and sodium caseinate, and that the particle  
507 characteristics can be tailored by manipulating the ratio of caseinate  
508 to gum arabic (Ye, Flanagan, & Singh, 2006). Such  
509 protein–carbohydrate nanoparticle complexes may be suitable  
510 vehicles for vitamin A encapsulation.

511 Encapsulation of lipophilic substances in polymer beads has been  
512 the subject of several patents. Mandralis and Tuot (1997) patented a  
513 process for encapsulating AAs in biopolymer particles by high  
514 pressure gelation of a natural polymer encapsulant. Catron and  
515 Mann (2000) produced beads loaded with hydrophobic AA by heat  
516 setting or chemically cross linking emulsion droplets. Lim and Moss  
517 (1983) devised a process in which alginate-containing emulsion  
518 droplets are solidified by immersion in alcoholic solutions of  
519 multivalent cations. A similar method using a mixture of cationic and  
520 anionic polymers is the subject of a patent application (Cattaneo,  
521 2005).

## 522           **7. Protein binding**

523    In living organisms, retinoids are non-covalently bound by proteins of  
524    the 'lipid-binding protein' family, which transport fatty acids and other  
525    small hydrophobic ligands in plants, animals and bacteria (De Wolf &  
526    Brett, 2000). Retinol may also be bound to proteins in food matrices,  
527    especially those containing lipid-binding whey proteins, e.g.  $\beta$ -  
528    lactoglobulin and bovine serum albumin (BSA).

529     $\beta$ -Lactoglobulin exists in bovine milk as a dimer at pH 6.5 with two  
530    binding sites per dimer, and has a tertiary structure very similar to  
531    those of retinol-binding proteins in the human body (Perez & Calvo,  
532    1995). The fluorescence of retinol is enhanced by  $\beta$ -lactoglobulin,  
533    because binding restricts the mobility of the retinol molecule, and  
534    fluorescence enhancement can be used to quantify binding affinity  
535    (Collini, D'Alfonso, Molinari, Ragona, Catalano, & Baldini, 2003).  
536    Retinoic acid dissociates from the retinoic acid- $\beta$ -lactoglobulin  
537    complex below pH 7.0 because of conformational changes in the  
538    protein, and will re-associate on neutralization (Zsila, Bikadi, &  
539    Simonyi, 2002).

540    Chemical derivatization of  $\beta$ -lactoglobulin can alter its functional  
541    properties, including retinoid binding. Methyl- or ethyl-alkylation of  $\beta$ -  
542    lactoglobulin improves the binding of retinol, retinoic acid, retinyl  
543    acetate and  $\beta$ -carotene (Dufour & Haertle, 1991). Hattori, Okada, and  
544    Takahashi (2000) reported that conjugating carboxymethyl CD to  $\beta$ -  
545    lactoglobulin improved the emulsifying activity and pH stability.

546 Antioxidant properties and retinol binding were not affected (Hattori  
547 et al., 2000).

548 In the work of Shimoyamada, Yoshimura, Tomida, and Watanabe  
549 (1996), retinoic acid or retinol complexed with  $\beta$ -lactoglobulin  
550 degraded more slowly than the uncomplexed retinoids during 6 h of  
551 UV irradiation. Hattori, Watabe, and Takahashi (1995) reported that  
552  $\beta$ -lactoglobulin protected retinol during irradiation and exposure to  
553 high temperature or acidic pH. Retinol retention was > 60% after 5 h  
554 at 60°C (compared with 30% without  $\beta$ -lactoglobulin); higher  
555 temperatures denatured the protein and destroyed the protective  
556 effect. More than 80% of the initial retinol was retained after 5 h at  
557 37°C and pH 3–9 (Hattori et al., 1995).

558 BSA also binds retinoids, resulting in enhanced fluorescence. BSA  
559 inhibits light-induced degradation of retinol to a similar extent to  $\beta$ -  
560 lactoglobulin, but does not protect retinoic acid (Shimoyamada et al.,  
561 1996).

562 Carotenes are bound to lipoproteins in some vegetables,  
563 cyanobacteria, animals and crustaceans. The structure and the  
564 biological function of carotenoproteins have been discussed in the  
565 literature (Flower, 1996), and there is potential to use them as means  
566 of encapsulating labile nutrients (De Wolf & Brett, 2000).

## 567 **8. Glassy matrix encapsulation**

568 Encapsulation of  $\beta$ -carotene in amorphous trehalose (a disaccharide)  
569 has been shown to slow degradation during extended storage,



570 provided the trehalose can be prevented from absorbing moisture  
571 and crystallizing (Elizalde, Herrera, & Buera, 2002). A process for  
572 encapsulating vitamins or minerals in glassy fructo-oligosaccharides  
573 has been patented (Leusner, Lakkis, van Lengerich, & Thomas,  
574 2002).

## 575 **9. Antioxidants**

576 Some antioxidants improve the stability of retinoids during exposure  
577 to light or oxygen. Butylated hydroxytoluene (BHT) is an oil-soluble  
578 phenolic antioxidant that competes with radical propagation  
579 reactions. Carlotti *et al.* (2002) reported that BHT slowed the  
580 degradation of retinyl palmitate under UV irradiation in a sealed  
581 container, but Failloux *et al.* (2004) found no effect in oxygenated  
582 retinol solution exposed to UV-A light. Retinoid destruction in  
583 oxygenated solutions kept in the dark was slowed by  $\alpha$ -tocopherol  
584 but not by  $\beta$ -carotene or ascorbic acid in the work of Ihara,  
585 Hashizume, Hirase, and Suzue (1999).

586 Antioxidants work well as an adjunct to other encapsulation  
587 techniques. For example, the retinol stability in O/W/O emulsions is  
588 improved by both oil-soluble (BHT) and water-soluble (sodium  
589 ascorbate) antioxidants (Yoshida *et al.*, 1999).

## 590 **Summary and conclusions**

591 Vitamin A supplementation via foods and/or pharmaceuticals has the  
592 potential to prevent disease and ensure healthy childhood  
593 development in developing countries. Technical barriers to delivering

594 vitamin A in foods include its poor dispersibility in aqueous systems  
595 and its vulnerability to degradation during processing, transport and  
596 storage. As the risk of overdosing precludes high dose fortification to  
597 compensate for losses, there is a need for technologies that slow  
598 vitamin A degradation.

599 Slowing the degradation of vitamin A relies on protecting it from  
600 influences that accelerate degradation, particularly UV light, chemical  
601 catalysts (especially metal contaminants and lipid hydroperoxides)  
602 and oxygen. Much of the research into technologies for protecting  
603 vitamin A does not examine the mechanistic rationale for an  
604 improvement in stability, but instead takes a 'screening' approach.

605 Vitamin A supplementation via foods requires that the amount of  
606 vitamin A present at the time of consumption is sufficiently high to be  
607 therapeutic and sufficiently low to minimise the risk of overdosing.  
608 Maintaining vitamin A activity within the bounds of safety and  
609 effectiveness requires limiting the loss of activity through oxidation  
610 and isomerization. It is therefore important to assess both the loading  
611 capacity of an encapsulation system (which depends on entrapment  
612 efficiency) and the stability of encapsulated vitamin A under  
613 conditions relevant to food processing and storage.

614 Table 2 summarises the loading capacity, entrapment efficiency and  
615 stability improvement of a range of vitamin A protection technologies  
616 discussed here. It is evident from table 2 that the entrapment  
617 efficiency of encapsulation systems is seldom measured. This is  
618 important because a significant proportion of vitamin A mixed with an

619 encapsulant can remain free in solution or adsorbed on surfaces,  
620 where it will be exposed to conditions that catalyse oxidation and/or  
621 isomerisation. Without a knowledge of encapsulation efficiency it is  
622 impossible to evaluate true loading capacity, and therefore difficult to  
623 compare the effectiveness of different systems. It is not possible to  
624 evaluate the commercial potential of diverse technologies based on  
625 information in the academic literature because the costs of  
626 ingredients are never disclosed in articles.

627 Also notable in Table 2 is a scarcity of technologies that use food-  
628 safe manufacturing processes. This probably results from the fact  
629 that much vitamin A stabilization research is oriented towards  
630 pharmaceutical applications, in which doses are low, or cosmetic  
631 products that are applied dermally and not consumed.

632 Emulsions can act as a vehicle for dispersing large amounts of  
633 hydrophobic material in an aqueous system. The photostability of  
634 labile nutrients is sometimes improved by emulsification, and synergy  
635 between oil- and water-soluble antioxidants is enhanced in these  
636 systems. Microemulsions and multiple emulsions have shown some  
637 promise in stabilizing hydrophobic nutrients, and warrant further  
638 investigation.

639 SLNs provide a physical barrier between retinoids and oxidation  
640 catalysts, and their light-scattering properties (Müller et al., 2002)  
641 reduce the intensity of light reaching the AAs entrapped in them.  
642 SLNs made with anionic stabilizers tend to aggregate at low pH, but  
643 non-ionic polymers can provide sufficient steric stabilization to

644 overcome this. Amphiphilic polymer stabilizers such as PEG  
645 derivatives and copolymers of polyoxyethylene and polyoxypropylene  
646 (trade names Pluronic, Poloxamer) provide effective steric  
647 stabilization at low pH.

648 Stabilization in solid lipid particles requires efficient incorporation and  
649 retention in the lipid matrix, which is best achieved with mixed lipids  
650 that form impure crystals, undercooled melts or oil droplets within a  
651 solid matrix. The lipid-soluble antioxidants butylated hydroxyanisole,  
652 BHT, propyl gallate and  $\alpha$ -tocopherol can further enhance the  
653 stability of lipid-encapsulated retinoids.

654 Entrapment in liposomes protects vitamin A under some conditions,  
655 but little protection is afforded at acidic pH and ambient or higher  
656 temperature. Some authors have reported accelerated degradation  
657 of vitamin A in liposomes, relative to free vitamin A. This has been  
658 speculatively attributed to the high local concentration inside  
659 liposomes, which presumably accelerates autoxidation.

660 Methods for preparing liposomes in the laboratory often use solvents  
661 that are unacceptable for food systems, and published results may  
662 be difficult to reproduce in food-safe systems. Liposomes can be  
663 made more robust with a protective coating (Ruan *et al.*, 2004) or by  
664 incorporation inside a multilayer encapsulation system (Evans &  
665 Zasadzinski, 2003).

666 Lipid cochleates are very effective at protecting and delivering drugs,  
667 but to date there have been no applications in foods, probably

668 because existing processes for making cochleates use toxic  
669 solvents. Cochleates may be useful as intermediates in the  
670 preparation of 'vesicles in vesicles' (Evans & Zasadzinski, 2003).

671 Retinoids may be more stable dispersed or dissolved in an aqueous  
672 phase than in lipid droplets or particles, for two reasons: (1) oxygen  
673 is less soluble in water than in lipids, and (2) lipid hydroperoxides are  
674 absent in the aqueous phase. Stability would be compromised if  
675 retinoids were brought into close contact with aqueous oxidation  
676 catalysts such as transition metal ions. The aqueous solubility of  
677 vitamin A is greatly improved by complexing with CDs.

678 Vitamin A has been incorporated into solid particles of proteins  
679 (gelatin, collagen, gliadin), carbohydrates (alginate, chitosan) and  
680 synthetic polymers (silicates, PLGA copolymers). Encapsulation  
681 processes have been reported and, in some cases, patented, but the  
682 stability of polymer-encapsulated vitamin A is not often evaluated in  
683 the literature. Polymer particles range in size from hundreds of  
684 nanometres to hundreds of micrometres, which may not be suitable  
685 for liquid foods.

686 Carotenoids are often complexed with proteins in biological systems,  
687 and vitamin A will form water-soluble complexes with certain  
688 proteins. BSA and  $\beta$ -lactoglobulin offer some protection against  
689 photo-oxidation, heating and acidic pH. Other plant or animal  
690 proteins may also form soluble complexes with retinoids that  
691 preserve vitamin A activity in food systems.

692 It is uncommon to find 'silver bullet' solutions to food preservation  
693 problems; a combination of approaches such as the 'hurdle-  
694 technology' concept (Leistner & Gorris, 1995) is more often  
695 successful. Protecting vitamin A is just such a problem, because  
696 retinoids and carotenoids must be stabilized against several chemical  
697 and physical degradation catalysts, and protection is often achieved  
698 at the expense of loading capacity. Synergistic protective effects are  
699 seen when individual technologies are combined, such as  
700 incorporating antioxidants into emulsions or SLNs, and encapsulating  
701 CD complexes inside liposomes. In our opinion, the most promising  
702 advances in vitamin A protection in foods will come from  
703 consideration of the multifaceted nature of vitamin degradation and  
704 the potential to combine technologies in ways that take advantage of  
705 their individual strengths.

706 **References**

707

708 Ames, S. R., Swanson, W. J., & Harris, P. L. (1955). Biochemical  
709 studies on vitamin A. XIV. Biopotencies of geometric isomers of  
710 vitamin A acetate in the rat. *Journal of the American Chemical*  
711 *Society*, 77(15), 4134-4136.

712 Ball, G. F. M. (1998). Vitamin A and the provitamin A carotenoids. In  
713 G. F. M. Ball (Ed.), *Bioavailability and analysis of vitamins in food*  
714 (pp. 115-162). London, UK: Chapman and Hall.

715 BioDelivery Sciences International. 2008. Bioral Technology.

716 <http://www.biodeliverysciences.com/technology/bioral.html>.

717 Accessed May 2008.

718 Brinkmann, E., Dehne, L., Oei, H. B., Tiebach, R., & Baltes, W.  
719 (1995). Separation of geometrical retinol isomers in food samples by  
720 using narrow-bore high-performance liquid-chromatography. *Journal*  
721 *of Chromatography A*, 693(2), 271-279.

722 Carlotti, M. E., Rossatto, V., & Gallarate, M. (2002). Vitamin A and  
723 vitamin A palmitate stability over time and under UVA and UVB  
724 radiation. *International Journal of Pharmaceutics*, 240(1-2), 85-94.

725 Carlotti, M. E., Sapino, S., Trotta, M., Battaglia, L., Vione, D., &  
726 Pelizzetti, E. (2005). Photostability and stability over time of retinyl  
727 palmitate in an O/W emulsion and in SLN introduced in the emulsion.  
728 *Journal of Dispersion Science and Technology*, 26(2), 125-138.

- 729 Catron, D. H., & Mann, O. J. (2000). Method and protecting heat- or  
730 oxygen-labile compounds to preserve activity and bioavailability.  
731 Kemin Industries Inc., US patent 6146671.
- 732 Cattaneo, M. V. (2005). Particles for the delivery of active agents.  
733 IVREA Pharmaceuticals, US patent application US20050281886 A1.
- 734 Cirpanli, Y., Unlu, N., Calis, S., & Hincal, A. A. (2005). Formulation  
735 and in-vitro characterization of retinoic acid loaded poly (lactic-co-  
736 glycolic acid) microspheres. *Journal of Microencapsulation*, 22(8),  
737 877-889.
- 738 Collini, M., D'Alfonso, L., Molinari, H., Ragona, L., Catalano, M., &  
739 Baldini, G. (2003). Competitive binding of fatty acids and the  
740 fluorescent probe 1-8-anilino-naphthalene sulfonate to bovine beta-  
741 lactoglobulin. *Protein Science*, 12(8), 1596-1603.
- 742 Cortesi, R., Esposito, E., Luca, G., & Nastruzzi, C. (2002). Production  
743 of lipospheres as carriers for bioactive compounds. *Biomaterials*,  
744 23(11), 2283-2294.
- 745 Dary, O., & Mora, J. O. (2002). Food fortification to reduce vitamin A  
746 deficiency: International Vitamin A Consultative Group  
747 recommendations. *Journal of Nutrition*, 132(9), 2927S-2933S.
- 748 De Wolf, F., & Brett, G. (2000). Ligand-binding proteins: their  
749 potential for application in systems for controlled delivery and uptake  
750 of ligands. *Pharmacological Reviews*, 52(2), 207-236.



- 751 Duchene, D., Ponchel, G., & Wouessidjewe, D. (1999). Cyclodextrins  
752 in targeting - application to nanoparticles. *Advanced Drug Delivery*  
753 *Reviews*, 36(1), 29-40.
- 754 Duclairoir, C., Irache, J. M., Nakache, E., Orecchioni, A. M.,  
755 Chabenat, C., & Popineau, Y. (1999). Gliadin nanoparticles:  
756 formation, all-trans-retinoic acid entrapment and release, size  
757 optimization. *Polymer International*, 48(4), 327-333.
- 758 Dufour, E., & Haertle, T. (1991). Binding of retinoids and beta-  
759 carotene to beta-lactoglobulin. Influence of protein modifications.  
760 *Biochimica et Biophysica Acta*, 1079(316-320).
- 761 El-Agamey, A., Lowe, G. M., McGarvey, D. J., Mortensen, A., Phillip,  
762 D. M., Truscott, T. G., *et al.* (2004). Carotenoid radical chemistry and  
763 antioxidant/pro-oxidant properties. *Archives of Biochemistry and*  
764 *Biophysics*, 430(1), 37-48.
- 765 Elizalde, B. E., Herrera, M. L., & Buera, M. P. (2002). Retention of  
766 beta-carotene encapsulated in a trehalose-based matrix as affected  
767 by water content and sugar crystallization. *Journal of Food Science*,  
768 67(8), 3039-3045.
- 769 Evans, C. C., & Zasadzinski, J. (2003). Encapsulating vesicles and  
770 colloids from cochleate cylinders. *Langmuir*, 19(8), 3109-3113.
- 771 Failloux, N., Bonnet, I., Perrier, E., & Baron, M. H. (2004). Effects of  
772 light, oxygen and concentration on vitamin A1. *Journal of Raman*  
773 *Spectroscopy*, 35(2), 140-147.

- 774 Farrell, H. M., Jr., Jimenez-Flores, R., Bleck, G. T., Brown, E. M.,  
775 Butler, J. E., Creamer, L. K., Hicks, C. L., Hollar, C. M., Ng-Kwai-  
776 Hang, K. F., & Swaisgood, H. E. (2004). Nomenclature of the  
777 Proteins of cows' milk - sixth revision. *Journal of Dairy Science*,  
778 87(6), 1641-1674.
- 779 Flanagan, J., Kortegaard, K., Pinder, D. N., Rades, T., & Singh, H.  
780 (2006). Solubilisation of soybean oil in microemulsions using various  
781 surfactants. *Food Hydrocolloids*, 20(2-3), 253-260.
- 782 Flanagan, J., & Singh, H. (2006). Microemulsions: a potential delivery  
783 system for bioactives in food. *Critical Reviews in Food Science and*  
784 *Nutrition*, 46(3), 221-237.
- 785 Flower, D. R. (1996). The lipocalin protein family: structure and  
786 function. *Biochemical Journal*, 318(Pt 1), 1-14.
- 787 Frankel, E. N. (2005). *Lipid oxidation* (2<sup>nd</sup> ed.). Bridgwater, UK: Oily  
788 Press.
- 789 Garcia-Fuentes, M., Alonso, M. J., & Torres, D. (2005). Design and  
790 characterization of a new drug nanocarrier made from solid-liquid  
791 lipid mixtures. *Journal of Colloid and Interface Science*, 285(2), 590-  
792 598.
- 793 Garcia-Fuentes, M., Torres, D., & Alonso, M. J. (2003). Design of  
794 lipid nanoparticles for the oral delivery of hydrophilic  
795 macromolecules. *Colloids and Surfaces B-Biointerfaces*, 27(2-3),  
796 159-168.

- 797 Garti, N., Abraham, A., Spernath, A., & Idit, A. (2007). Nano-sized  
798 self-assembled liquid dilutable vehicles. NutraLease Ltd., US patent  
799 7182950.
- 800 Garti, N., Yaghmur, A., Aserin, A., Spernath, A., Elfakess, R., &  
801 Ezrahi, S. (2004). Solubilization of active molecules in  
802 microemulsions for improved environmental protection. *Colloids and*  
803 *Surfaces A: Physicochemical and Engineering Aspects*, 230, 183-  
804 190.
- 805 Gasco, M. (2002). Solid lipid microspheres having a narrow size  
806 distribution and method for producing them. European patent EP  
807 0526666 B2.
- 808 Guo, Q. X., Ren, T., Fang, Y. P., & Liu, Y. C. (1995). Binding of  
809 vitamin A by beta-cyclodextrin and heptakis(2,6-o-dimethyl)-beta-  
810 cyclodextrin. *Journal of Inclusion Phenomena and Molecular*  
811 *Recognition in Chemistry*, 22(4), 251-256.
- 812 Hähnlein, W., Hanse, M. M., & Olesen, J. E. (1998). Stable  
813 emulsions and dry powder from mixtures of fat-soluble vitamins, their  
814 process of preparation and their use. BASF AG, European patent EP  
815 0835613.
- 816 Hattori, M., Okada, Y., & Takahashi, K. (2000). Functional changes in  
817 beta-lactoglobulin upon conjugation with carboxymethyl cyclodextrin.  
818 *Journal of Agricultural and Food Chemistry*, 48(9), 3789-3794.
- 819 Hattori, M., Watabe, A., & Takahashi, K. (1995). Beta-lactoglobulin  
820 protects beta-ionone related compounds from degradation by

- 821 heating, oxidation, and irradiation. *Bioscience Biotechnology and*  
822 *Biochemistry*, 59(12), 2295-2297.
- 823 Hu, F. Q., Jiang, S. P., Du, Y. Z., Yuan, H., Ye, Y. Q., & Zeng, S.  
824 (2005). Preparation and characterization of stearic acid  
825 nanostructured lipid carriers by solvent diffusion method in an  
826 aqueous system. *Colloids and Surfaces B: Biointerfaces*, 45(3-4),  
827 167-173.
- 828 Hwang, Y. J., Oh, C., & Oh, S. G. (2005). Controlled release of  
829 retinol from silica particles prepared in O/W/O emulsion: the effects  
830 of surfactants and polymers. *Journal of Controlled Release*, 106(3),  
831 339-349.
- 832 Ihara, H., Hashizume, N., Hirase, N., & Suzue, R. (1999).  
833 Esterification makes retinol more labile to photolysis. *Journal of*  
834 *Nutritional Science and Vitaminology*, 45(3), 353-358.
- 835 Jennings, V., & Gohla, S. (2000). Comparison of wax and glyceride  
836 solid lipid nanoparticles (SLN(R)). *International Journal of*  
837 *Pharmaceutics*, 196(2), 219-222.
- 838 Jennings, V., & Gohla, S. (2001). Encapsulation of retinoids in solid  
839 lipid nanoparticles (SLN). *Journal of Microencapsulation*, 18(2), 149-  
840 158.
- 841 Jeong, Y. I., Song, J. G., Kang, S. S., Ryu, H. H., Lee, Y. H., Choi,  
842 C., *et al.* (2003). Preparation of poly(DL-lactide-co-glycolide)  
843 microspheres encapsulating all-trans retinoic acid. *International*  
844 *Journal of Pharmaceutics*, 259(1-2), 79-91.

- 845 Jin, T. (2004). Cochleates without metal cations as the bridging  
846 agents. WIPO patent application WO 2004012709 A1.
- 847 Jores, K., Haberland, A., Wartewig, S., Mäder, K., & Mehnert, W.  
848 (2005). Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by  
849 spectrofluorometry and Raman spectroscopy. *Pharmaceutical*  
850 *Research*, 22(11), 1887-1897.
- 851 Krause-Elsmore, S., & Mannino, R. (2005). Rigid liposomal cochleate  
852 and methods of use and manufacture. Biodelivery Sciences  
853 International Inc., WIPO patent WO 2005063213 A1.
- 854 Lee, M. H., Oh, S. G., Moon, S. K., & Bae, S. Y. (2001). Preparation  
855 of silica particles encapsulating retinol using O/W/O multiple  
856 emulsions. *Journal of Colloid and Interface Science*, 240(1), 83-89.
- 857 Lee, S. C., Yuk, H. G., Lee, D. H., Lee, K. E., Hwang, Y. I., &  
858 Ludescher, R. D. (2002). Stabilization of retinol through incorporation  
859 into Liposomes. *Journal of Biochemistry and Molecular Biology*,  
860 35(4), 358-363.
- 861 Leistner, L., & Gorris, L. G. M. (1995). Food Preservation by Hurdle  
862 Technology. *Trends in Food Science and Technology*, 6(2), 41-46.
- 863 Leusner, S. J., Lakkis, J., van Lengerich, B. H., & Thomas, J. (2002).  
864 Oligosaccharide encapsulated mineral and vitamin ingredients.  
865 General Mills, US patent 6468568.
- 866 Lim, F., & Moss, R. D. (1983). Vitamin encapsulation. Damon  
867 Corporation, USA patent US 4389419.

- 868 Lim, S. J., & Kim, C. K. (2002). Formulation parameters determining  
869 the physicochemical characteristics of solid lipid nanoparticles loaded  
870 with all-trans retinoic acid. *International Journal of Pharmaceutics*,  
871 243(1-2), 135-146.
- 872 Lim, S. J., Lee, M. K., & Kim, C. K. (2004). Altered chemical and  
873 biological activities of all-trans retinoic acid incorporated in solid lipid  
874 nanoparticle powders. *Journal of Controlled Release*, 100(1), 53-61.
- 875 Lin, H. S., Chean, C. S., Ng, Y. Y., Chan, S. Y., & Ho, P. C. (2000).  
876 2-Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and  
877 photostability of all-trans-retinoic acid. *Journal of Clinical Pharmacy*  
878 *and Therapeutics*, 25(4), 265-269.
- 879 Loftsson, T. (1994). Cyclodextrin complexation. Cyclops h.f., US  
880 patent 5472954.
- 881 Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications  
882 of cyclodextrins.1. Drug solubilization and stabilization. *Journal of*  
883 *Pharmaceutical Sciences*, 85(10), 1017-1025.
- 884 Loftsson, T., Matthiasson, K., & Masson, M. (2003). The effects of  
885 organic salts on the cyclodextrin solubilization of drugs. *International*  
886 *Journal of Pharmaceutics*, 262(1-2), 101-107.
- 887 Loukas, Y. L., Jayasekera, P., & Gregoriadis, G. (1995). Novel  
888 liposome-based multicomponent systems for the protection of  
889 photolabile agents. *International Journal of Pharmaceutics*, 117(1),  
890 85-94.

- 891 Lucks, S., & Müller, R. H. (1996). Medication vehicles made of solid  
892 lipid particles (solid lipid nanospheres - SLN). Medac GmbH,  
893 European patent EP 0605497 B2.
- 894 Manconi, M., Valenti, D., Sinico, C., Lai, F., Loy, G., & Fadda, A. M.  
895 (2003). Niosomes as carriers for tretinoin. II. Influence of vesicular  
896 incorporation on tretinoin photostability. *International Journal of*  
897 *Pharmaceutics*, 260(2), 261-272.
- 898 Mandralis, Z. I., & Tuot, J. (1997). Process for encapsulating a core  
899 material with a polymer by high-pressure treatments. Nestle S.A.,  
900 European patent EP 0750854 A2.
- 901 Mannino, R., & Krause-Elsmore, S. (2004). Cochleate preparations  
902 of fragile nutrients. BioDelivery Sciences International Inc., WIPO  
903 patent application WO 2004064805 A1.
- 904 Mauguet, M. C., Legrand, J., Brujes, L., Carnelle, G., Larre, C., &  
905 Popineau, Y. (2002). Gliadin matrices for microencapsulation  
906 processes by simple coacervation method. *Journal of*  
907 *Microencapsulation*, 19(3), 377-384.
- 908 McClements, D. J., Decker, E. A., & Weiss, J. (2007). Emulsion-  
909 based delivery systems for lipophilic bioactive components. *Journal*  
910 *of Food Science*, 72(8), R109-R124.
- 911 McCormack, B., & Gregoriadis, G. (1998). Drugs-in-cyclodextrins-in-  
912 liposomes: an approach to controlling the fate of water insoluble  
913 drugs in vivo. *International Journal of Pharmaceutics*, 162(1-2), 59-  
914 69.

- 915 McPhail, D., Tetley, L., Dufes, C., & Uchegbu, I. F. (2000).  
916 Liposomes encapsulating polymeric chitosan based vesicles - a  
917 vesicle in vesicle system for drug delivery. *International Journal of*  
918 *Pharmaceutics*, 200(1), 73-86.
- 919 Moldenhauer, J. P., Regiert, M., & Wimmer, T. (1999). Complexes of  
920 gamma-cyclodextrin and retinol or retinol derivatives, processes for  
921 their preparation and use. Wacker-Chemie GmbH, US patent  
922 5985296.
- 923 Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles  
924 for controlled drug delivery - a review of the state of the art.  
925 *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1),  
926 161-177.
- 927 Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid  
928 nanoparticles (SLN) and nanostructured lipid carriers (NLC) in  
929 cosmetic and dermatological preparations. *Advanced Drug Delivery*  
930 *Reviews*, 54, S131-S155.
- 931 Munoz-Botella, S., Martin, M. A., Del Castillo, B., Lerner, D. A., &  
932 Menendez, J. C. (2002). Differentiating geometrical isomers of  
933 retinoids and controlling their photo-isomerization by complexation  
934 with cyclodextrins. *Analytica Chimica Acta*, 468(1), 161-170.
- 935 Palozza, P., Muzzalupo, R., Trombino, S., Valdannini, A., & Picci, N.  
936 (2006). Solubilization and stabilization of beta-carotene in niosomes:  
937 delivery to cultured cells. *Chemistry and Physics of Lipids*, 139(1),  
938 32-42.



- 939 Panfili, G., Manzi, P., & Pizzoferrato, L. (1998). Influence of thermal  
940 and other manufacturing stresses on retinol isomerization in milk and  
941 dairy products. *Journal of Dairy Research*, 65(2), 253-260.
- 942 Perez, M. D., & Calvo, M. (1995). Interaction of beta-lactoglobulin  
943 with retinol and fatty acids and its role as a possible biological  
944 function for this protein: a review. *Journal of Dairy Science*, 78(5),  
945 978-988.
- 946 Polyakov, N. E., Leshina, T. V., Konovalova, T. A., Hand, E. O., &  
947 Kispert, L. D. (2004). Inclusion complexes of carotenoids with  
948 cyclodextrins: 1HNMR, EPR, and optical studies. *Free Radical*  
949 *Biology and Medicine*, 36(7), 872-880.
- 950 Qi, Z. H., & Shieh, W. J. (2002). Aqueous media for effective delivery  
951 of tretinoin. *Journal of Inclusion Phenomena and Macrocyclic*  
952 *Chemistry*, 44(1-4), 133-136.
- 953 Ribeiro, A. J., Neufeld, R. J., Arnaud, P., & Chaumeil, J. C. (1999).  
954 Microencapsulation of lipophilic drugs in chitosan-coated alginate  
955 microspheres. *International Journal of Pharmaceutics*, 187(1), 115-  
956 123.
- 957 Rozanowska, M., Cantrell, A., Edge, R., Land, E. J., Sarna, T., &  
958 Truscott, T. G. (2005). Pulse radiolysis study of the interaction of  
959 retinoids with peroxy radicals. *Free Radical Biology and Medicine*,  
960 39(10), 1399-1405.
- 961 Ruan, G., Ng, J. K., & Feng, S. S. (2004). Effects of polymer, organic  
962 solvent and mixing strength on integrity of proteins and liposomes

- 963 encapsulated in polymeric microspheres fabricated by the double  
964 emulsion process. *Journal of Microencapsulation*, 21(4), 399-412.
- 965 Santangelo, R., Paderu, P., Delmas, G., Chen, Z. W., Mannino, R.,  
966 Zarif, L., *et al.* (2000). Efficacy of oral cochleate-amphotericin B in a  
967 mouse model of systemic candidiasis. *Antimicrobial Agents and*  
968 *Chemotherapy*, 44(9), 2356-2360.
- 969 Sapino, S., Carlotti, M. E., Pelizzetti, E., Vione, D., Trotta, M., &  
970 Battaglia, L. (2005). Protective effect of SLNs encapsulation on the  
971 photodegradation and thermal degradation of retinyl palmitate  
972 introduced in hydroxyethylcellulose gel. *Journal of Drug Delivery*  
973 *Science and Technology*, 15(2), 159-165.
- 974 Schlenk, H., Sand, D., & Tillotson, J. (1955). Stabilization of  
975 materials. University of Minnesota, US patent 2827452.
- 976 Schwieter, U., & Isler, O. (1971). II. Chemistry. In O. Isler, G.  
977 Gutmann & U. Solms (Eds.), *Carotenoids* (pp. 5-35). Basel, Stuttgart:  
978 Birkhäuser-Verlag.
- 979 Semenova, E. M., Cooper, A., Wilson, C. G., & Converse, C. A.  
980 (2002). Stabilization of all-trans-retinol by cyclodextrins: a  
981 comparative study using HPLC and fluorescence spectroscopy.  
982 *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 44(1-4),  
983 155-158.
- 984 Shimoyamada, M., Yoshimura, H., Tomida, K., & Watanabe, K.  
985 (1996). Stabilities of bovine beta-lactoglobulin/retinol or retinoic acid  
986 complexes against tryptic hydrolysis, heating and light-induced

- 987 oxidation. *Lebensmittel-Wissenschaft und -Technologie*, 29(8), 763-  
988 766.
- 989 Singh, A. K., & Das, J. (1998). Liposome encapsulated vitamin A  
990 compounds exhibit greater stability and diminished toxicity.  
991 *Biophysical Chemistry*, 73(1-2), 155-162.
- 992 Swatschek, D., Schatton, W., Müller, E. E. G., & Kreuter, J. (2002).  
993 Microparticles derived from marine sponge collagen (SCMPs):  
994 preparation, characterization and suitability for dermal delivery of all-  
995 trans retinol. *European Journal of Pharmaceutics and*  
996 *Biopharmaceutics*, 54(2), 125-133.
- 997 Szejtli, J. (1998). Introduction and general overview of cyclodextrin  
998 chemistry. *Chemical Reviews*, 98(5), 1743-1753.
- 999 Szente, L. (1996). Preparation of cyclodextrin complexes. In J. Szejtli  
1000 & T. Osa (Eds.), *Comprehensive supramolecular chemistry* (Vol. 3,  
1001 pp. 243-252). New York, NY: Pergamon Press.
- 1002 Szymula, M. (2004). Atmospheric oxidation of beta-carotene in  
1003 aqueous, pentanol, SDS microemulsion systems in the presence and  
1004 absence of vitamin C. *Journal of Dispersion Science and*  
1005 *Technology*, 25(2), 129-137.
- 1006 Takeshi, Y., & Okihiko, S. (1994). Stabilization of vitamin A. Shiseido  
1007 Corporation Ltd., Japanese patent JP 6032774.
- 1008 Tesoriere, L., Darpa, D., Re, R., & Livrea, M. A. (1997). Antioxidant  
1009 reactions of all-trans retinol in phospholipid bilayers: effect of oxygen

- 1010 partial pressure, radical fluxes, and retinol concentration. *Archives of*  
1011 *Biochemistry and Biophysics*, 343(1), 13-18.
- 1012 Villamor, E., & Fawzi, W. W. (2005). Effects of Vitamin A  
1013 supplementation on immune responses and correlation with clinical  
1014 outcomes. *Clinical Microbiology Reviews*, 18(3), 446-464.
- 1015 Walker, S. A., Kennedy, M. T., & Zasadzinski, J. (1997).  
1016 Encapsulation of bilayer vesicles by self-assembly. *Nature*, 387(1),  
1017 61-64.
- 1018 Weiser, H., & Somorjai, G. (1992). Bioactivity of cis and dicis isomers  
1019 of vitamin A esters. *International Journal for Vitamin and Nutrition*  
1020 *Research*, 62(3), 201-208.
- 1021 Yaghmur, A., DeCampo, L., Sagalowicz, L., Leser, M., Glatter, O.,  
1022 Michel, M., *et al.* (2007). Oil-in-water emulsion for delivery. Nestec  
1023 S.A., US patent application 20070213234 A1.
- 1024 Yap, K. L., Liu, X., Thenmozhiyal, J. C., & Ho, P. C. (2005).  
1025 Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion  
1026 complexes by phase solubility, photostability, physicochemical and  
1027 computational analysis. *European Journal of Pharmaceutical*  
1028 *Sciences*, 25(1), 49-56.
- 1029 Ye, A., Flanagan, J., & Singh, H. (2006). Formation of stable nano-  
1030 particles via electrostatic complexation between sodium caseinate  
1031 and gum arabic. *Biopolymers*, 82(2), 121-133.

1032 Yoshida, K., Sekine, T., Matsuzaki, F., Yanaki, T., & Yamaguchi, M.  
1033 (1999). Stability of vitamin A in oil-in-water-in-oil-type multiple  
1034 emulsions. *Journal of the American Oil Chemists' Society*, 76(2),  
1035 195-200.

1036 Young, A. M., & Gregoriadis, G. (1996). Photolysis of retinol in  
1037 liposomes and its protection with tocopherol and oxybenzone.  
1038 *Photochemistry and Photobiology*, 63(3), 344-352.

1039 Zarif, L. (2005). Drug delivery by lipid cochleates. *Methods in*  
1040 *Enzymology*, 391, 314-329.

1041 Zarif, L., Jin, T., Segarra, I., & Mannino, R. (2005). Novel cochleate  
1042 formulations. University of Medicine and Dentistry of New Jersey, US  
1043 patent application 20050186265.

1044 Zsila, F., Bikadi, Z., & Simonyi, M. (2002). Retinoic acid binding  
1045 properties of the lipocalin member beta-lactoglobulin studied by  
1046 circular dichroism, electronic absorption spectroscopy and molecular  
1047 modeling methods. *Biochemical Pharmacology*, 64(11), 1651-1660.

1048

1049


1050

1051 This work was funded by BASF, Germany and the NZ Foundation for  
1052 Research, Science and Technology. The authors thank BioDelivery  
1053 Sciences International Inc. for permission to reproduce figure 2.

1054

1055

1056




1057

1058

1059 **Fig. 1.** Structure of selected retinoids, where R is one of: A, retinol;

1060 B, retinoic acid; C, retinaldehyde; D, retinyl palmitate.



1061

1062 **Fig. 2.** Schematic representation of nanocochleate structure.

1063 Copyright BioDelivery Sciences International, Inc.

1064 **Table 1. Relative vitamin A activity of retinyl acetate isomers.**

RA <sup>a</sup> isomer	Relative vitamin A activity <sup>b</sup>	
	Ames <i>et al.</i> (1955)	Weiser and Somorjai (1992)
<i>all-trans</i>	100	100
<i>13-cis</i>	75	76
<i>11-cis</i>		31
<i>9-cis</i>	22	19
<i>7-cis</i>		18
<i>9,13-di-cis</i>	24	16
<i>11,13-di-cis</i>	23	18

1065

1066 <sup>a</sup>RA, retinyl acetate1067 <sup>b</sup>the activity of the *all-trans* isomer is arbitrarily designated as 100%

1068



1069 **Table 2. Ability of various encapsulation systems to entrap and protect vitamin A.**

reference	technology	food safe?	AA <sup>a</sup>	loading capacity <sup>b</sup> % w/w	entrapment efficiency <sup>c</sup> %	stability improvement
Yoshida <i>et al.</i> (1999)	O/W/O emulsion	?	RO	0.47	83.5	after storage at 50°C for 4 weeks, 60% of retinol remained, while retinol in paraffin was completely degraded.
Jenning & Gohla (2001)	glyceryl behenate SLN	yes	RO	10 <sup>d</sup>	ND <sup>e</sup>	after storage at 40°C for 160 days, 60% of retinol remained, compared with 50% of retinol in an O/W emulsion
Carlotti <i>et al.</i> (2005)	cetyl palmitate SLN in cosmetic O/W emulsion	?	RP	9 <sup>d</sup>	ND	after UV irradiation for 120 min, 70% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion
	glyceryl behenate SLN in cosmetic O/W emulsion	?	RP	9 <sup>d</sup>	ND	after UV irradiation for 120 min, 51% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion
	palmitic acid SLN in cosmetic O/W emulsion	?	RP	5.6 <sup>d</sup>	ND	after UV irradiation for 120 min, 66% of retinol in SLN remained, compared with 8% of retinol in an O/W emulsion

Lee <i>et al.</i> (2002)	PC and soybean oil liposomes	no	RO	0.99	99.25 ± 0.47	after 8 days at 25°C, pH 7.0 without light, 50% of retinol in liposomes remained, while free retinol in buffer was completely degraded  after 8 days at 25°C, pH 7.0 under UV light, 20% of retinol in liposomes remained, while free retinol in buffer was completely degraded
Munoz-Botella <i>et al.</i> (2002)	β-cyclodextrin complex	no	ATRA	0.13 <sup>d</sup>	ND	after exposure to light for 60 min, 44.3% of ATRA with β-CD remained in <i>all-trans</i> form, compared with 31.8% for ATRA in ethanol
	DM-β-cyclodextrin <sup>f</sup> complex	no	ATRA	0.11 <sup>d</sup>	ND	after exposure to light for 60 min, 54.6% of ATRA with DM-β-CD <sup>f</sup> remained in <i>all-trans</i> form, compared with 31.8% of ATRA in ethanol
Lin <i>et al.</i> (2000)	2-HP-β-cyclodextrin <sup>g</sup> complex	yes	ATRA	0.57 <sup>d</sup>	ND	after exposure to light at 40°C for 6 h, 22% of ATRA with HP-β-CD <sup>g</sup> remained, compared with 18% of ATRA in methanol
Lee <i>et al.</i> (2001)	silica microspheres	no	RO	2.23-2.82	35.9-44.0	not tested
Hwang <i>et al.</i> (2005)	silica microspheres	no	RO	not reported	7.4-30.9	not tested
Jeong <i>et al.</i> (2003)	polymer particles	no	ATRA	1.66-8.83	27.1-54.9	not tested
Duclairoir <i>et al.</i>	gliadin nanoparticles	yes	ATRA	7.64	75	not tested

(1999)

Shimoyamada <i>et al.</i> (1996)	$\beta$ -lactoglobulin complex	yes	RO	1.3 <sup>d,h</sup>	ND	after 6 h under UV light, 92% of retinol remained, while 45% of free retinol remained.
Hattori <i>et al.</i> (1995)	$\beta$ -lactoglobulin complex	yes	RO	0.7 <sup>d,h</sup>	ND	after holding at 50°C for 5 h, 80% of retinol with $\beta$ -lactoglobulin remained, while 25% of retinol in buffer remained.  after exposure to fluorescent light for 5 h, 36% of retinol with $\beta$ -lactoglobulin remained, while 20% of retinol in buffer remained.

1071 <sup>a</sup>active agent: RO, retinol; RP, retinyl palmitate; ATRA, all-*trans* retinoic acid

1072 <sup>b</sup> loading capacity =  $\frac{\text{entrapped AA}}{\text{entrapped AA} + \text{matrix}} \times 100$

1073 <sup>c</sup> entrapment efficiency =  $\frac{\text{total AA} - \text{unentrapped AA}}{\text{total AA}} \times 100$

1074 <sup>d</sup>nominal loading capacity, assuming 100% entrapment efficiency

1075 <sup>e</sup>not determined

1076 <sup>f</sup>DM- $\beta$ -cyclodextrin, DM- $\beta$ -CD: heptakis (2,6-O-dimethyl)-beta-cyclodextrin

1077 <sup>g</sup>HP- $\beta$ -cyclodextrin, HP- $\beta$ -CD: hydroxypropyl-beta-cyclodextrin

1078 <sup>h</sup>calculated from concentrations of  $\beta$ -lactoglobulin and retinol using the molecular weight of  $\beta$ -lactoglobulin-A reported in Farrell *et al.*,  
1079 2004

1080

1081

# Recent advances in technologies for vitamin A protection in foods.

Loveday, SM

2008